Capabilities
-
Litigation Support; Expert Witness
- Depositions; Jury Trial Testimony
- Defense (52%); Plaintiff (48%)
-
Medical Records Review
-
Pre-Clinical Toxicology Support
- Study Data Review and Analysis
- Report Preparation
- Peer Review
- Risk Characterization
- Comparative Risk
-
Over 250 Chemicals of Interest, including:
Benzene
Bisphenol-A (BPA)
Chlorinated solvents
DEHP
1,2-Dichloroethane
Formaldehyde
Lead
Metals
Methylene chloride
Perchloroethylene (PERC)
Phthalates
Terephthalic acid
Toluene
Trichloroethylene (TCE)
Xylene
-
Drugs of Interest include:
Alcohol
Botox (e.g., Botulinum neurotoxin Type A)
Ciprofloxacin
Cocaine
Cyclosporine A
Demerol
Dilantin
Keflex (i.e., Cephalosporin)
Levaquin
Librium
Lithium
Mellaril
Methadone
Mineral Oil
Morphine
Penicillin
Prilosec
Progesterone
Prozac (fluoxetine)
Soma
Viagra
Xanax (alprazolam)
Zyprexa (olanzapine)
-
Acute Respiratory Distress Syndrome (ARDS)
-
Bisphenol-A (BPA) and Endocrine Disruption
-
Children's Health
-
Endocrine Disruption
-
Lead
-
Morphine Intoxication
-
Random Drug Testing
-
Rhabdomyolysis
-
Sewer Gas
-
Stevens-Johnson Syndrome
-
Toxic-Epidermal Necrolysis
-
Regulatory Submissions and Responses -- EPA, FDA
-
Monitoring -- scientific conferences, workshops and regulatory agency meetings
Examples of Past Projects
-
Expert Witness and litigation support since 1998, including deposition and jury trial testimony, for Defense and Plaintiff in toxicology, carcinogenesis (cancer causation), pharmacology, and pharmacy standards of care.
-
Expert technical report preparation in support of company responses to FDA and EPA requests.
-
Provided expert professional advice at strategy sessions on environmental regulatory policies and considerations.
-
A review of chemical contaminants in food, water and breast milk.
-
A review of published studies that do not support the endocrine disruption hypothesis.
-
A report on the lack of consensus on endocrine disruption.
-
Poster presentations and poster monitoring at the International Symposiums on Environmental Endocrine Disruptors in Japan ('99 and '00).
-
...and many, many more.
Relevant Scientific Publications
-
Milman, H.A., Bosland, M.C., Walden, P.D. and Heinze, J.E.: Evaluation of the adequacy of published studies of low dose effects of bisphenol A (BPA) on the rodent prostate for use in human risk assessment. Regul. Toxicol. Pharmacol. 35:338-346 (2002).
-
Milman, H.A., and Heinze, J.E.: Evaluation of the relationship between children's health and exposure to endocrine disrupters. Abstracts, 3rd Annual Meeting of the Japan Society of Endocrine Disrupters Research. PE-18:336 (2000).
-
Over 70 scientific publications and abstracts and numerous governmental reports (see PUBLICATIONS).
Contact:
ToxNetwork.com
© Copyright 2000; 2005 ToxNetwork.com
Revised January 2008